04.12.25 -- Outsourced Pharma Best Of March

This article shares an overview of market research on GLP-1 drugs, including the anticipated growth of the market and the current leaders in the space.

Delve into the manufacturing and synthesizing technologies used to manufacture GLP-1 drugs, in addition to the novel drug delivery technologies being used.

There has been limited guidance for assessing new or elevated impurity levels. To address this, the EMA has issued a "reflection paper" to consider what is needed for a safety evaluation and how to make assessments. The public comment period ends April 30.

Market dynamics will continue to favor engaging with CDMO partners who have the capabilities and experience to manage short-term needs while anticipating and planning for long-term requirements.

Technology transfer is a crucial process in the pharmaceutical industry, ensuring drugs developed in labs can be manufactured consistently at scale.

In this session, Chief Scientific Officer Dr. Andy Lewis delves into the key drivers shaping peptide drug development and explores innovative delivery options to enhance therapeutic outcomes.